Immunotherapeutic potential of blinatumomab-secreting γ9δ2 T Cells

Schwerdtfeger, 2021, Chimeric antigen receptor-modified T cells and T cell-engaging bispecific antibodies: different tools for the same job, Curr. Hematol. Malig. Rep., 16, 218, 10.1007/s11899-021-00628-2 Molina, 2021, CAR T cells better than BiTEs, Blood Adv., 5, 602, 10.1182/bloodadvances.2020003554 Subklewe, 2021, BiTEs better than CAR T cells, Blood Adv., 5, 607, 10.1182/bloodadvances.2020001792 Wu, 2015, Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia, J. Hematol. Oncol., 8, 104, 10.1186/s13045-015-0195-4 Kantarjian, 2017, Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia, New Eng. J. Med., 376, 836, 10.1056/NEJMoa1609783 Yu, 2019, Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis, Hematology, 24, 199, 10.1080/16078454.2018.1549802 Zhou, 2021, The landscape of bispecific T cell engager in cancer treatment, Biomark. Res., 9, 38, 10.1186/s40364-021-00294-9 Zhu, 2016, Blinatumomab, a bispecific T-cell engager (BiTE((R))) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications, Clin. Pharmacokinet., 55, 1271, 10.1007/s40262-016-0405-4 Einsele, 2020, The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types, Cancer, 126, 3192, 10.1002/cncr.32909 Jain, 2018, No free rides: management of toxicities of novel immunotherapies in ALL, including financial, Blood Adv., 2, 3393, 10.1182/bloodadvances.2018020198 Blanco, 2022, Overcoming CAR-mediated CD19 downmodulation and leukemia relapse with T lymphocytes secreting anti-CD19 T-cell engagers, Cancer Immunol. Res., 10, 498, 10.1158/2326-6066.CIR-21-0853 Velasquez, 2016, T cells expressing CD19-specific engager molecules for the immunotherapy of CD19-positive Malignancies, Sci. Rep., 6, 27130, 10.1038/srep27130 Liu, 2016, Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice, Blood Cancer J., 6, e430, 10.1038/bcj.2016.38 Choi, 2019, CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity, Nature Biotechnol., 37, 1049, 10.1038/s41587-019-0192-1 Majzner, 2018, Tumor antigen escape from CAR T-celltherapy, Cancer Discov., 8, 1219, 10.1158/2159-8290.CD-18-0442 Blanco, 2020, Engineering immune cells for in vivo secretion of tumor-specific T cell-redirecting bispecific antibodies, Front. Immunol., 11, 1792, 10.3389/fimmu.2020.01792 Zheng, 2013, gammadelta-T cells: an unpolished sword in human anti-infection immunity, Cell. Mol. Immunol., 10, 50, 10.1038/cmi.2012.43 Ribot, 2011, Searching for "signal 2": costimulation requirements of gammadelta T cells, Cell. Mol. Life Sci., 68, 2345, 10.1007/s00018-011-0698-2 Zumwalde, 2017, Adoptively transferred Vgamma9Vdelta2 T cells show potent anti-tumor effects in a preclinical B cell lymphomagenesis model, JCI Insight, 2, 10.1172/jci.insight.93179 Kunkele, 2020, Vgamma9Vdelta2 T cells: can we re-purpose a potent anti-infection mechanism for cancer therapy?, Cells, 9, 10.3390/cells9040829 Sanz, 2022, Human Vdelta2 T cells and their versatility for immunotherapeutic approaches, Cells., 11, 10.3390/cells11223572 Ferrarini, 2008, NF-kappa B modulates sensitivity to apoptosis, proinflammatory and migratory potential in short- versus long-term cultured human gamma delta lymphocytes, J. Immunol., 181, 5857, 10.4049/jimmunol.181.9.5857 Tomogane, 2021, Human Vgamma9Vdelta2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells, Biochem. Biophys. Res. Commun., 573, 132, 10.1016/j.bbrc.2021.08.005 Huang, 2017, Relationship between PD-L1 expression and CD8+ T-cell immune responses in hepatocellular carcinoma, J. Immunother., 40, 323, 10.1097/CJI.0000000000000187 Wilhelm, 2014, Successful adoptive transfer and in vivo expansion of haploidentical gammadelta T cells, J. Transl. Med., 12, 45, 10.1186/1479-5876-12-45 Aldoss, 2017, Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia, Am. J. Hematol., 92, 858, 10.1002/ajh.24783 Sheehy, 2001, A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis, J. Immunol. Methods, 249, 99, 10.1016/S0022-1759(00)00329-X Chen, 2021, The potential of adoptive transfer of gamma9delta2 T cells to enhance blinatumomab's anti-tumor activity against B-cell malignancy, Sci. Rep., 11, 12398, 10.1038/s41598-021-91784-1 Clendening, 2010, Dysregulation of the mevalonate pathway promotes transformation, Proc. Nat. Acad. Sci. U.S.A., 107, 15051, 10.1073/pnas.0910258107 Roelofs, 2009, Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP, Br. J. Haematol., 144, 245, 10.1111/j.1365-2141.2008.07435.x Kondo, 2008, Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy, Cytotherapy, 10, 842, 10.1080/14653240802419328 Lang JM, Kaikobad MR, Wallace M, Staab MJ, Horvath DL, Wilding G, et al. Pilot trial of interleukin-2 and zoledronic acid to augment gammadelta T cells as treatment for patients with refractory renal cell carcinoma. Cancer immunology, immunotherapy: CII. 2011;60:1447-60. doi:10.1007/s00262-011-1049-8. Blanco, 2019, Cell-redirecting strategies to 'STAb' tumors: beyond CARs and bispecific antibodies, Trends Immunol., 40, 243, 10.1016/j.it.2019.01.008 Hosseini, 2017, Ex vivo expansion of CD3(depleted) cord blood-MNCs in the presence of bone marrow stromal cells; an appropriate strategy to provide functional NK cells applicable for cellular therapy, Stem Cell Res., 19, 148, 10.1016/j.scr.2017.01.010 Ghasemzadeh, 2022, Exhausted NK cells and cytokine storms in COVID-19: whether NK cell therapy could be a therapeutic choice, Hum. Immunol., 83, 86, 10.1016/j.humimm.2021.09.004 Velasquez, 2017, CD28 and 41BB costimulation enhances the effector function of CD19-specific engager T cells, Cancer Immunol. Res., 5, 860, 10.1158/2326-6066.CIR-17-0171 Perales-Puchalt, 2019, DNA-encoded bispecific T cell engagers and antibodies present long-term anti-tumor activity, JCI Insight, 4, 10.1172/jci.insight.126086 Yu, 2019, A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells, J. Exp. Clin. Cancer Res., 38, 355, 10.1186/s13046-019-1354-1 Bhojnagarwala, 2022, In vivo DNA-launched bispecific T cell engager targeting IL-13Ralpha2 controls tumor growth in an animal model of glioblastoma multiforme, Mol. Ther. Oncolytics, 26, 289, 10.1016/j.omto.2022.07.003 Yin, 2022, Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors, Mol. Therapy, 30, 2537, 10.1016/j.ymthe.2022.05.011